Artios Pharma nabs $84 mln Series B
UK-based Artios Pharma Limited, a DNA damage response company developing treatments for cancer, has closed $84 million in Series B financing. Andera Partners and LSP led the round with participation from Pfizer Ventures, Novartis Venture Fund, Arix Bioscience, SV Health Investors, M Ventures, IP Group plc and AbbVie Ventures.
10 August 2018•1 min read
